Abstract
Resveratrol is biologically active, but the clean marketing story—one red-wine molecule, one SIRT1 switch, one route to longer life—did not survive careful testing. Controlled human trials have reported changes in metabolic, cerebrovascular or cognitive surrogate measures. Other well-controlled trials in non-obese women, men with obesity and patients with fatty liver have been null. The record does not support a simple rule that resveratrol works whenever metabolism is impaired, nor has a trial shown that it slows human aging or extends life.
Pharmacokinetics help explain why results vary. Oral resveratrol is substantially absorbed, yet unchanged parent compound is rapidly converted to sulfate and glucuronide conjugates. The original broad claim of direct SIRT1 activation also depended on a fluorescent assay substrate; later work supports a narrower, substrate-dependent possibility and indirect SIRT1-linked pathways in experimental systems. Normal-diet mouse lifespan studies were null. A full six-tablet labelled serving of Geroprotect Essentials II contains 360 mg of Resveratrol. That is a transparent composition fact, not clinical validation of the ingredient or finished formula.
01 · Identity
A plant defence molecule with two identities
Resveratrol is 3,5,4′-trihydroxystilbene, a stilbenoid made by plants in response to stress. Trans-resveratrol is the isomer used in most modern human trials; light can promote conversion toward the cis form. That chemistry matters because an evidence comparison requires the actual isomer, purity, source and delivery form—not merely the word “resveratrol.”
The current public Geroprotect Formula page lists Resveratrol. It does not publicly specify an isomer percentage, botanical source, particle size or finished-batch assay. This review therefore does not assume that the formula material is the 99% trans-resveratrol used in one trial, the micronized SRT501 preparation used in another, or a particular Japanese-knotweed extract. Those preparations should not be treated as interchangeable without analytical documentation.
Resveratrol is often introduced as “the molecule in red wine.” That is chemically true but pharmacologically misleading: supplement trials generally use isolated amounts far above dietary exposure. Evidence from a defined capsule cannot be transferred to wine, and evidence about wine cannot be assigned to resveratrol alone.
02 · Human trials
Bioactive signals, strong nulls and no simple subgroup rule
A widely cited crossover study gave 11 otherwise healthy men with obesity 150 mg/day of 99% trans-resveratrol for 30 days. It reported lower sleeping and resting energy expenditure, systolic blood pressure, intrahepatic lipid and several metabolic markers, with no change in body weight.1 This was a rich physiology experiment, but it was small, short and measured many surrogate endpoints. DSM supplied the active and placebo capsules, performed resveratrol analyses, and employed one co-author. The result is evidence of short-term biological activity in that setting, not a longevity outcome.
A second small trial randomised 19 men with type 2 diabetes to 10 mg/day or placebo for four weeks. HOMA-IR and platelet Akt phosphorylation changed favourably.2 HOMA-IR is a calculated surrogate, the sample was small, and the trial did not establish fewer complications or a durable clinical benefit.
The null trials are equally important. In 29 non-obese postmenopausal women with normal glucose tolerance, 75 mg/day for 12 weeks did not change clamp-measured insulin sensitivity, body composition, resting metabolic rate, plasma lipids or skeletal-muscle SIRT1, AMPK, NAMPT and PGC-1α measures.3 DSM provided product and grant support. In an investigator-initiated trial of 24 otherwise healthy men with obesity, 1,500 mg/day for four weeks did not improve the clamp primary outcome, glucose turnover, blood pressure, body fat, liver fat or inflammatory and metabolic markers.4
A trial in 20 men with non-alcoholic fatty liver disease used 3,000 mg/day for eight weeks. It found no improvement in insulin resistance, steatosis or abdominal fat and reported increases in ALT and AST.5 That is a high-dose result in a selected clinical population, not evidence of liver injury at 360 mg. It does, however, defeat the idea that a larger dose reliably produces a larger benefit.
| Study | Tested exposure | What it can establish |
|---|---|---|
| Timmers et al. | 11 men with obesity; 150 mg/day; 30-day crossover | Several short-term metabolic surrogate signals; very small, multi-endpoint study. |
| Brasnyó et al. | 19 men with type 2 diabetes; 10 mg/day; four weeks | Positive HOMA-IR and signalling measures; no clinical-event or longevity endpoint. |
| Yoshino et al. | 29 non-obese women; 75 mg/day; 12 weeks | Null clamp and molecular results in metabolically normal participants. |
| Poulsen et al. | 24 men with obesity; 1,500 mg/day; four weeks | Null clamp primary outcome and broad metabolic panel despite high exposure. |
| Chachay et al. | 20 men with fatty liver; 3,000 mg/day; eight weeks | Null metabolic and imaging findings, with higher liver enzymes at a high dose. |
The human record is not confined to metabolism. RESHAW used a 24-month, double-blind crossover design in 125 postmenopausal women: 75 mg of trans-resveratrol twice daily for 12 months, then the alternate treatment for 12 months. Its prespecified overall-cognition primary outcome favoured resveratrol, but the standardised effect was small (Cohen’s d = 0.170); several cerebrovascular measures also changed.21 This is substantive positive human evidence. It is still one population, one branded synthetic preparation and a test-battery outcome—not evidence of dementia prevention or slower aging. Evolva supplied the test material and supplementary funding; the paper states that it had no role in design, data collection, analysis, interpretation or writing.
At the other end of the clinical spectrum, 119 people with mild-to-moderate Alzheimer disease were randomised for 52 weeks to placebo or resveratrol escalating from 500 mg/day to 1,000 mg twice daily. Resveratrol and metabolites were measurable in cerebrospinal fluid, and some Aβ40 trajectories differed. Whole-brain volume loss was greater with resveratrol, while MMSE, ADAS-cog, CDR, NPI and several other clinical or biomarker measures did not differ.22 The investigators described the altered trajectories as uncertain and not evidence of benefit. This study establishes central exposure and ambiguity, not an Alzheimer treatment claim.
These trials do not justify the manuscript’s original claim that resveratrol generally works in people with metabolic dysfunction and generally fails in healthy people. Obesity produced both a positive and a null trial. Fatty liver produced a high-dose null. Type 2 diabetes has a positive small study, while results across related metabolic populations vary. Population, background treatment, preparation, endpoint and chance all remain plausible sources of heterogeneity. Most importantly, none of these studies established a validated rate-of-aging endpoint, mortality effect or efficacy of the 13-active Essentials II formula.
03 · Exercise
One important interaction signal—not a timing rule
Gliemann and colleagues randomised 27 healthy, physically inactive men aged 60–72 to 250 mg/day of trans-resveratrol or placebo during eight weeks of high-intensity exercise training. Peak oxygen uptake improved in both groups, but the increase was 45% greater in the placebo group; mean arterial pressure fell only with placebo, and several lipid and vascular adaptations were attenuated with resveratrol.6
This is a credible caution against assuming that antioxidant-labelled compounds always add to exercise. It is still one small male-only study of a specific dose, training programme and age range. It does not show that resveratrol universally “cancels exercise,” and it did not test whether taking a capsule at a different time of day prevents the interaction. The source manuscript’s proposed evening or away-from-workout schedule is therefore removed; timing advice cannot be manufactured from this design.
04 · Exposure
High absorption, low free parent and a conjugate-rich circulation
In a radiolabel study of six volunteers, at least 70% of a 25 mg oral dose was absorbed. Peak plasma resveratrol plus metabolites was about 491 ng/mL, yet unchanged resveratrol remained below 5 ng/mL. Sulfation, glucuronidation and microbial hydrogenation accounted for much of the recovered dose.7 “Poor bioavailability” therefore does not mean that the dose stays in the capsule; it means that very little circulates as unchanged parent molecule.
A 29-day dose-escalation study in healthy volunteers tested 0.5, 1, 2.5 and 5 g/day. Major sulfate and glucuronide conjugate concentrations exceeded parent resveratrol, often by several-fold.8 Some conjugates may have biological activity or act as tissue reservoirs in experimental models, but that possibility does not rescue every cell-culture claim. Many cell studies expose cells directly to micromolar free resveratrol; an oral capsule produces a different mixture, time course and tissue distribution.
05 · SIRT1
The fluorescent tag mattered; the whole pathway did not disappear
The modern resveratrol story accelerated in 2003, when a fluorescent peptide assay identified resveratrol as an apparent activator of the NAD-dependent deacetylase SIRT1.9 The assay used a peptide carrying a hydrophobic fluorophore. That detail became decisive.
Beher and colleagues found activation with the fluorescent substrate but not with an unlabelled p53-derived peptide.10 Pacholec and colleagues likewise found that resveratrol and several synthetic compounds failed to activate SIRT1 against native peptide or full-length protein substrates; their binding studies implicated the fluorophore-containing substrate.11 Those experiments invalidated a broad assay-independent claim of direct activation.
The later answer was not simply “never.” Hubbard and colleagues reported activation with selected unlabelled peptide sequences containing hydrophobic residues near the acetylated lysine and showed dependence on SIRT1’s amino-terminal activation domain.12 That paper deserves its disclosure context: numerous authors were Sirtris/GSK employees, David Sinclair was a consultant and inventor on licensed patents, and related patent applications were identified. The data support a substrate-assisted, sequence-dependent model; they do not establish universal activation of endogenous SIRT1 targets in a person taking an oral supplement.
A separate cell-and-mouse study proposed that resveratrol inhibits cAMP phosphodiesterases, raising cAMP and engaging Epac1, CaMKKβ, AMPK, NAD and then SIRT1-linked signalling.13 It is a useful indirect mechanism, not proof that PDE4 is the dominant human target at 360 mg. The most accurate summary is narrower than both marketing and debunking: resveratrol can influence SIRT1-linked biology in experimental systems, while “direct SIRT1 activator” remains too imprecise for an unqualified product claim.
06 · Lifespan
Rescuing a high-calorie model is not extending normal mammalian life
In a famous 2006 experiment, middle-aged male mice fed a high-calorie diet plus resveratrol had a 31% lower hazard of death than high-calorie controls and survival statistically indistinguishable from standard-diet controls.14 This was an important rescue in a diet-stress model. It was not evidence that resveratrol lengthens the life of normally fed mammals.
That distinction was tested directly. Pearson and colleagues reported several age-related functional and molecular changes in middle-aged mice, but standard-diet animals given resveratrol did not live longer.15 The National Institute on Aging Interventions Testing Program then tested resveratrol at 300 and 1,200 ppm, beginning at 12 months, in genetically heterogeneous mice across three sites. Neither dose significantly altered survival in males or females.16
The source manuscript attributed this paper to Strong in 2013. The primary publication is Miller and colleagues, 2011; Randy Strong was a co-author. More importantly, no human randomised trial has tested resveratrol against lifespan or all-cause mortality. A molecule can affect a pathway or biomarker without extending life. For resveratrol, that boundary is not semantic—it is the central evidence result.
07 · Combination claims
A pathway diagram is not a synergy experiment
The source manuscript proposed quercetin, spermidine, berberine and NAD precursors as evidence-based partners. The evidence does not support that wording in humans.
| Proposed partner | What was actually tested | Conclusion |
|---|---|---|
| Quercetin | Laboratory human-liver and duodenal preparations suggested inhibition of resveratrol sulfation. In eight healthy people taking 2 g resveratrol twice daily, 500 mg quercetin twice daily did not change resveratrol pharmacokinetics.17 | “Quercetin boosts resveratrol bioavailability” is not supported by the located human PK experiment. |
| Spermidine | Low-dose resveratrol plus spermidine increased autophagy markers in cultured HCT116 cells and after intraperitoneal injection in mice.18 | Interesting experimental synergy; not an oral human trial and not evidence for the Geroprotect combination. |
| Berberine or NAD precursors | Pathway overlap and animal experiments can motivate a hypothesis. No component-controlled human trial of the current amounts was located. | Complementarity remains a formulation rationale, not a demonstrated additive or synergistic outcome. |
| Pterostilbene | The molecules are chemical relatives with overlapping targets and different pharmacokinetics. The combined Geroprotect exposure has not been isolated clinically. | Neither redundancy nor benefit from using both has been established in people. |
Geroprotect’s two formulas place resveratrol alongside multiple actives with mechanistic overlap. That can be stated as design intent. It cannot be called a clinically validated network effect until a trial separates the complete combination from its components and measures a prespecified human outcome.
08 · Safety
Reassuring lower-dose context without hiding high-dose findings
In the 29-day healthy-volunteer escalation study, no serious adverse reaction was detected across 0.5 to 5 g/day. Mild-to-moderate gastrointestinal symptoms—especially diarrhoea, nausea, abdominal discomfort and flatulence—were concentrated at 2.5 and 5 g/day.8 The current 360 mg labelled amount is below the lowest arm of that study. That is reassuring context, but it does not prove long-term safety of a 13-active formula.
The 3 g/day fatty-liver trial’s transaminase increase belongs to that high dose and population.5 The most serious renal report came from 5 g/day of micronized SRT501 in relapsed or refractory multiple myeloma. Five serious renal-failure events led to early termination; several affected patients had pre-existing renal impairment, progressive myeloma, vomiting, dehydration or other relevant exposures.19 The investigators judged the profile unacceptable in that population. It should not be rewritten as routine kidney toxicity at 360 mg in healthy customers.
Medicine interactions also require calibration. In 40 evaluable healthy volunteers, 1 g/day for four weeks changed metabolic ratios used as probes for CYP1A2, CYP3A4, CYP2D6 and CYP2C9 activity.20 The study did not test clinical outcomes with long-term co-medications, and 1 g is nearly three times the Geroprotect amount. Laboratory platelet effects likewise do not establish a clinical bleeding rate at 360 mg. Still, people using anticoagulant, antiplatelet or narrow-therapeutic-index medicines, or planning a procedure, should have the complete multi-ingredient formula reviewed by a clinician or pharmacist. That is ordinary precaution, not evidence that routine harm is expected.
09 · Formula context
What 360 mg in Essentials II does—and does not—mean
A full six-tablet labelled serving of Geroprotect Essentials II contains 360 mg of Resveratrol. The amount sits within the broad range used in human research, but no trial reviewed here tested the current material specification, all 13 Essentials II actives or the combined 26-active system.
The evidence supports describing resveratrol as a well-studied stilbenoid with measurable human exposure and inconsistent short-term effects on selected surrogate endpoints. It supports discussing AMPK-, SIRT1-, cAMP- and autophagy-linked research as mechanisms under investigation. It does not support promising lower blood pressure, better glucose control, exercise enhancement, age reversal or longer life to a generally healthy customer.
| Statement | Evidence verdict |
|---|---|
| Oral resveratrol reaches the body | Supported, mainly as conjugated metabolites rather than high circulating free parent. |
| Resveratrol directly switches on SIRT1 | Too broad. Early assays were fluorophore-dependent; later direct activation is substrate-selective and contested in physiological translation. |
| Resveratrol improves human metabolic health | Not established as a general claim. Small positive surrogate trials coexist with strong nulls. |
| Resveratrol extends mammalian lifespan | Not supported in normally fed mice; no human lifespan trial exists. |
| The Geroprotect stack is synergistic | Untested. Cell and mouse combinations are hypotheses, not component-controlled human evidence. |
| 360 mg is clinically validated | No. It is a transparent labelled amount, not a proven stand-alone or finished-formula intervention. |
Questions
Frequently asked questions
Does resveratrol work in people?
It produces measurable exposure and some small trials report changes in metabolic or vascular surrogate markers. Other rigorous trials are null. No controlled trial shows that resveratrol slows human aging, extends life or validates Essentials II.
Was the SIRT1 story completely debunked?
The original broad direct-activation claim was weakened because activation depended on a fluorescent assay substrate. Later experiments support activation of selected substrate sequences and indirect SIRT1-linked signalling. The accurate answer is qualified and substrate-dependent, not “universal switch” or “no biology at all.”
Does low free bioavailability mean resveratrol cannot do anything?
No. Much of an oral dose is absorbed, but it is rapidly converted into sulfate and glucuronide conjugates. Those metabolites and tissue exposure may matter. The limitation is that oral exposure cannot be equated with the free concentrations used in many cell experiments.
Should resveratrol be timed away from exercise?
One small trial found that 250 mg/day attenuated several training adaptations in older men. It did not compare morning, evening or workout-separated timing, so this review does not invent a timing protocol.
Does quercetin make resveratrol more bioavailable?
That idea arose from laboratory metabolism work. In a small human pharmacokinetic experiment, quercetin did not change resveratrol exposure. No human result validates the Geroprotect combination as a bioavailability strategy.
Is the renal warning relevant to 360 mg?
The severe renal signal came from 5 g/day of micronized SRT501 in people with advanced multiple myeloma, many with important competing renal risks. It should be disclosed but not extrapolated into a routine-risk claim for healthy users at 360 mg. Kidney disease and medicines still warrant individual review of the complete formula.
Primary sources
References
- Timmers S, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism. 2011;14:612–622. DOI 10.1016/j.cmet.2011.10.002.
- Brasnyó P, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition. 2011;106:383–389. DOI 10.1017/S0007114511000316.
- Yoshino J, et al. Resveratrol supplementation does not improve metabolic function in non-obese women with normal glucose tolerance. Cell Metabolism. 2012;16:658–664. DOI 10.1016/j.cmet.2012.09.015.
- Poulsen MM, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial. Diabetes. 2013;62:1186–1195. DOI 10.2337/db12-0975.
- Chachay VS, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2014;12:2092–2103.e6. DOI 10.1016/j.cgh.2014.02.024.
- Gliemann L, et al. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. Journal of Physiology. 2013;591:5047–5059. DOI 10.1113/jphysiol.2013.258061.
- Walle T, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition. 2004;32:1377–1382. DOI 10.1124/dmd.104.000885.
- Brown VA, et al. Repeat dose study of resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Research. 2010;70:9003–9011. DOI 10.1158/0008-5472.CAN-10-2364.
- Howitz KT, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191–196. DOI 10.1038/nature01960.
- Beher D, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chemical Biology & Drug Design. 2009;74:619–624. DOI 10.1111/j.1747-0285.2009.00901.x.
- Pacholec M, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. Journal of Biological Chemistry. 2010;285:8340–8351. DOI 10.1074/jbc.M109.088682.
- Hubbard BP, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science. 2013;339:1216–1219. DOI 10.1126/science.1231097.
- Park SJ, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148:421–433. DOI 10.1016/j.cell.2012.01.017.
- Baur JA, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337–342. DOI 10.1038/nature05354.
- Pearson KJ, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending lifespan. Cell Metabolism. 2008;8:157–168. DOI 10.1016/j.cmet.2008.06.011.
- Miller RA, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. Journal of Gerontology: Biological Sciences. 2011;66A:191–201. DOI 10.1093/gerona/glq178.
- la Porte C, et al. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2,000 mg twice daily with food, quercetin and alcohol in healthy subjects. Clinical Pharmacokinetics. 2010;49:449–454. DOI 10.2165/11531820-000000000-00000.
- Morselli E, et al. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. Journal of Cell Biology. 2011;192:615–629. DOI 10.1083/jcb.201008167.
- Popat R, et al. A phase 2 study of SRT501 with bortezomib for patients with relapsed or refractory multiple myeloma. British Journal of Haematology. 2013;160:714–717. DOI 10.1111/bjh.12154.
- Chow HHS, et al. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prevention Research. 2010;3:1168–1175. DOI 10.1158/1940-6207.CAPR-09-0155.
- Thaung Zaw JJ, Howe PRC, Wong RHX. Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: a 24-month randomised, double-blind, placebo-controlled, crossover study. Clinical Nutrition. 2021;40:820–829. DOI 10.1016/j.clnu.2020.08.025.
- Turner RS, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85:1383–1391. DOI 10.1212/WNL.0000000000002035.










